cancer doctors

Prostate Cancer Metastasis

Question: PSA and Tumor Markers for Prostate Bone Metastasis? This message pertains to the utility of Prostate Specific Antigen (PSA), for the treatment of Advanced Prostate Cancer. PSA writes Dr. John Lee (Harmone Balance for Men) is produced both within the Prostate Gland and the Breast Tissue. He further writes that the normal cells produce PSA, an anti angiogenesis defence when there are abnormally growing cells in the prostate. This seems to indicate that the PSA has no correlation with what is happening in the bone and anywhere outside prostate. Is this correct? There are further questions: (a) How do we monitor bone metastasis and other situations where the cancer has escaped out of prostate. (non-Bone Scan/MRI options) (b) Are there other prostate tumor markers that can tell us the tumor loads/tumor activity in non prostate areas such as the bones. (c) Will Acid Phosphatase levels inform us the status of prostate metastasis on bone. (d) Are Osteoblastic/Osteocystic/Osteocytic rates right parameters to track. Sam

Answer: There are a few misconceptions here. * PSA is manufactured almost exclusively by prostate cells. Although there are a few other cell types that can make minute quantities of it, their contribution is so small that PSA is indeed, for all practical purposes, a prostate-_specific_ marker. However, that doesn't mean it measures only cells that reside in the prostate gland. * In a person with normal prostatic health, prostate cells reside only in the prostate gland. But in a person with advanced prostate cancer, most of his prostate cells have traveled to areas outside the prostate, typically the bones and lungs. Therefore, for men with advanced prostate cancer, PSA is normally the single best way of tracking the cancer, since it correlates so well with the number of prostate cells in the body -- both within the gland (if it's still there) and outside the gland, and thus presumably cancerous. (a) To specifically find bone metastases, one would normally use an imaging technique, such as a bone scan, a CT scan, and/or a PET scan (preferably one that uses 11C-choline rather than 18F-FDG). It's unclear why someone would try to monitor bone metastasis without any attempt to image the bones, so I don't know what prompts the question. (Not all imaging techniques use radioactive tracers, for example. And if expense is an issue, then maybe consider simple X-rays.) (b) There are indeed other tumor markers, but none of them are specific to rogue prostate cells that are in the _bones_, as opposed to rogue prostate cells generally. Such tumor markers include: PSMA, PAP, NSE, CGA, and CEA. (c) Yes and no. PAP (prostatic acid phosphatase) is useful as a tumor marker, but no tumor marker, so far as I know, can possibly differentiate betwee bone and non-bone metastasis. (d) Yes and no. If you're focusing only on the bone, then you are interested in overall rates of bone-building (osteoblastic) and bone-resorption (osteoclastic) activity. But you won't know _where_ the activity is occurring. Most importantly: In a person has advanced prostate cancer, bone issues are one of the consequences. But it's much more important to tend to the cancer itself than to focus on only one of its consequences. If a car is heading downhill and its brakes are failing, one of the consequences will be tiretread left on the roadway. Rather than trying to measure and track the tiretread, it's more important to find a turnoff, or a soft ditch, or (best) an alternate braking system. Good luck! (BTW, I'm now also a member of the PCa tribe.)


Prostate Cancer Metastasis News

MD News (press release)

Metastatic Prostate Cancer Often Untreated
MedPage Today
 

13WMAZ

Amgen's Xgeva faces doubters on new indication
FiercePharma
 

Beyond the Abstract - Palliation and survival after repeated 188Re-HEDP ...

UroToday
BERKELEY, CA (UroToday.com) - Approximately 50% of prostate cancer patients develop bone metastases which are predominantly osteoblastic ? a type that has a tendency towards fractures, resulting in serious morbidity. This type of bone metastasis often ...
 

GU Cancers Symposium 2012 - A randomized phase II study of OGX-427 + ...

UroToday
The investigational compound OGX-427 is designed to inhibit the production of the heat shock protein 27 (hsp27), a cell survival protein expressed in many types of cancers including prostate, bladder, breast and non-small cell lung cancer.
 

The Oncology Report

ALSYMPCA Trial: Radium-223 Prolongs Life in Some Prostate Cancers
The Oncology Report
 

ThirdAge

Prostate Cancer Bone Mets Target of New Agent
MedPage Today
 

Risk profiles of prostate cancers identified from UK primary care using ...

UroToday
Objective: Prostate cancer in the United Kingdom is mainly diagnosed from primary care referrals based on national guidelines published by the Department of Health. Here we investigated the characteristics of cancers detected through the use of these ...
 

Molecular Insight Pharmaceuticals, Inc. Presents Human Data Demonstrating ...

MarketWatch (press release)
CAMBRIDGE, MA, Feb 02, 2012 (MARKETWIRE via COMTEX) -- Molecular Insight Pharmaceuticals, Inc. (MIP) will present first human data on the molecular imaging of metastatic prostate cancer in bone and soft tissue with their new 99mTc-radiolabeled ...
 

USA TODAY

Writer Vince Flynn aims for a 'Kill Shot' against cancer
USA TODAY
 

Vaccine Eyed for Early-Stage Prostate Ca

MedPage Today
Point out that the trial also confirmed the expected immune-cell responses when given outside of the approved setting in patients with metastatic prostate cancer. SAN FRANCISCO -- The immunotherapy agent sipuleucel-T (Provenge) appears safe for use ...
 

Types of Cancer


Adrenal Cancer Anal Cancer Brain Cancer Colorectal Cancer Endometrial Cancer Esophageal Cancer
Esophageal Cancer Laryngeal Cancer Oral Cancer Penile Cancer Prostatic Cancer Stomach Cancer
Thyroid Cancer Bladder Cancer Bone Cancer Cervix Cancer Heart Cancer Kidney Cancer
Melanoma Cancer Pancreas Cancer Asbestos Cancer